I-Mab (IMAB) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Dec 15Dec 18Dec 23Dec 29Mar 10Mar 13Mar 18Mar 23

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−45.8x

Market Cap

$235.29M

MomentumView details →

1D Return

−0.69%

YTD Return

−28.54%

RSI (14)

29.1

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−45.8x

Market Cap

$235.29M

RSI (14)

29.1

MomentumView details →

1D Return

−0.69%

YTD Return

−28.54%

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−19.42%

ROA (TTM)

−18.48%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−100.00%

EPS YoY

+91.39%

FCF YoY

—

Revenue CAGR 3Y

−100.00%

EPS CAGR 3Y

+74.69%

EBITDA YoY

+95.82%

EarningsView details →

EPS (Actual)

−$0.25

EPS Surprise

−316.67%

Beats (12Q)

4/12

Next Q EPS Est

—

Avg Surprise (4Q)

−77.40%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

22.82x

Quick Ratio

22.82x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−38.21M

Op. CF (TTM)

0.00

Latest newsMore news →

NovaBridge Biosciences reported financial results for the six months ended June 30, 2026, and provided a business update on pipeline momentum and strategic execution.15d ago

Similar companies

Greenwich LifeSciences, Inc.GLSI Protara Therapeutics, Inc.TARA Innate Pharma S.A.IPHA Acumen Pharmaceuticals, Inc.ABOS Avidity Biosciences, Inc.RNA Sol-Gel Technologies Ltd.SLGL Find similar companies →

Latest newsMore news →

NovaBridge Biosciences reported financial results for the six months ended June 30, 2026, and provided a business update on pipeline momentum and strategic execution.15d ago